Compositions comprising amino lipid compounds and methods of making and use thereof

Patent metadata

Field	Value
Publication number	US-2025032415-A1
Application number	US-202218708499-A
Country	US
Kind code	A1
Filing date	Nov 9, 2022
Priority date	Nov 11, 2021
Publication date	Jan 30, 2025
Grant date	—

Abstract

Disclosed herein are compositions comprising amino lipid compounds and methods of making and use thereof.

First claim

1 . A composition comprising a compound defined by Formula I, or a pharmaceutically acceptable salt thereof:

wherein
R 10 is substituted or unsubstituted C 1 -C 5 alkyl;
R 11 is substituted or unsubstituted C 1 -C 5 alkyl;
R 12 , R 13 , and R 14 are each independently substituted or unsubstituted C 6 -C 20 alkyl;
with the proviso that when R 10 is —C 5 H 10 — and R 11 is —C 3 H 6 —, then R 12 , R 13 , and R 14 are not all

and
with the proviso that when R 10 is —C 5 H 10 — and R 11 is —C 3 H 6 —, then R 12 , R 13 , and R 14 are not all

2 . (canceled)

3 . (canceled)

4 . (canceled)

5 . (canceled)

6 . The composition of claim 1 , wherein the compound is defined by Formula I-A:

or a pharmaceutically acceptable salt thereof.

7 . (canceled)

8 . The composition of claim 1 , wherein the compound is defined by Formula I-B, or a pharmaceutically acceptable salt thereof:

wherein n is an integer from 1 to 5.

9 . (canceled)

10 . (canceled)

11 . (canceled)

12 . The composition of claim 1 , wherein R 12 , R 13 , and R 14 are each independently a substituted or unsubstituted C 10 -C 18 alkyl.

13 . (canceled)

14 . (canceled)

15 . (canceled)

16 . (canceled)

17 . (canceled)

18 . Tag composition of claim 1 , wherein the compound is defined by Formula I-C, or a pharmaceutically acceptable salt thereof:

wherein n is an integer from 1 to 4.

19 . The composition of claim 1 , wherein the compound is selected from the group consisting of:

pharmaceutically acceptable salts thereof, and combinations thereof.

20 . (canceled)

21 . (canceled)

22 . (canceled)

23 . The composition of claim 1 , wherein the compound is selected from the group consisting of:

pharmaceutically acceptable salts thereof, and combinations thereof.

24 . A composition comprising a compound defined by Formula II, or a pharmaceutically acceptable salt thereof:

wherein
R 15 is substituted or unsubstituted C 1 -C 5 alkyl;
R 16 is substituted or unsubstituted C 1 -C 5 alkyl;
R 17 , R 18 , and R 19 are each independently substituted or unsubstituted C 6 -C 20 alkyl;
with the proviso that when R 15 is —C 5 H 10 — and R 16 is —C 3 H 6 —, then R 17 , R 18 , and R 19 are not all

and
with the proviso that when R 15 is —C 5 H 10 — and R 16 is —C 3 H 6 —, then R 17 , R 18 , and R 19

25 . (canceled)

26 . (canceled)

27 . (canceled)

28 . (canceled)

29 . The composition of claim 24 , wherein the compound is defined by Formula II-A:

or a pharmaceutically acceptable salt thereof.

30 . (canceled)

31 . The composition of claim 24 , wherein the compound is defined by Formula II-B, or a pharmaceutically acceptable salt thereof:

wherein m is an integer from 1 to 5.

32 . (canceled)

33 . (canceled)

34 . (canceled)

35 . The composition of claim 24 , wherein R 17 , R 18 , and R 19 are each independently a substituted or unsubstituted C 10 -C 18 alkyl.

36 . (canceled)

37 . (canceled)

38 . (canceled)

39 . (canceled)

40 . (canceled)

41 . The composition of claim 24 , wherein the compound is selected from the group consisting of:

pharmaceutically acceptable salts thereof, and combinations thereof.

42 . (canceled)

43 . (canceled)

44 . The composition of claim 24 , wherein the compound is selected from the group consisting of:

pharmaceutically acceptable salts thereof, and combinations thereof.

45 . A composition comprising a compound defined by Formula III, or a pharmaceutically acceptable salt thereof:

wherein
R 20 is substituted or unsubstituted C 1 -C 5 alkyl; and
R 21 and R 22 are each independently substituted or unsubstituted C 6 -C 20 alkyl.

46 . (canceled)

47 . (canceled)

48 . (canceled)

Assignees

• Ohio State Innovation Foundation

Inventors

• Dong Yizhou
• Xue Yonger
• Zhang Yuebao

Classifications

• A61K47/183

  Amino acids, e.g. glycine, EDTA or aspartame · CPC title

• A61K47/18

  Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids · CPC title

• A61K9/1617 Primary

  Organic compounds, e.g. phospholipids, fats · CPC title

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title

• A61K47/44

  Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14) · CPC title